Banque Cantonale Vaudoise’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-740
| Closed | -$102K | – | 927 |
|
|
2024
Q2 | $102K | Sell |
740
-446
| -38% | -$61.5K | ﹤0.01% | 688 |
|
|
2024
Q1 | $164K | Buy |
1,186
+787
| +197% | +$109K | 0.01% | 596 |
|
|
2023
Q4 | $53K | Sell |
399
-1,295
| -76% | -$172K | ﹤0.01% | 788 |
|
|
2023
Q3 | $191K | Sell |
1,694
-2,705
| -61% | -$305K | 0.01% | 692 |
|
|
2023
Q2 | $415K | Sell |
4,399
-3,440
| -44% | -$325K | 0.02% | 527 |
|
|
2023
Q1 | $793K | Buy |
7,839
+3,400
| +77% | +$344K | 0.04% | 352 |
|
|
2022
Q4 | $530K | Sell |
4,439
-55
| -1% | -$6.57K | 0.03% | 434 |
|
|
2022
Q3 | $476K | Buy |
4,494
+64
| +1% | +$6.78K | 0.03% | 489 |
|
|
2022
Q2 | $432K | Sell |
4,430
-11,670
| -72% | -$1.14M | 0.02% | 529 |
|
|
2022
Q1 | $1.51M | Buy |
16,100
+11,600
| +258% | +$1.09M | 0.07% | 295 |
|
|
2021
Q4 | $383K | Hold |
4,500
| – | – | 0.01% | 654 |
|
|
2021
Q3 | $432K | Sell |
4,500
-619
| -12% | -$59.4K | 0.02% | 603 |
|
|
2021
Q2 | $498K | Buy |
5,119
+3,700
| +261% | +$360K | 0.02% | 589 |
|
|
2021
Q1 | $137K | Buy |
1,419
+30
| +2% | +$2.9K | 0.01% | 839 |
|
|
2020
Q4 | $133K | Buy |
1,389
+589
| +74% | +$56.4K | 0.01% | 800 |
|
|
2020
Q3 | $77K | Sell |
800
-1,500
| -65% | -$144K | ﹤0.01% | 860 |
|
|
2020
Q2 | $280K | Buy |
+2,300
| New | +$280K | 0.02% | 560 |
|
|
2020
Q1 | – | Sell |
-926
| Closed | -$100K | – | 933 |
|
|
2019
Q4 | $100K | Buy |
+926
| New | +$100K | 0.01% | 809 |
|